The National Taiwan University Hospital is a medical facility located in the Zhongzheng District of Taipei, Taiwan. It started operations under Japanese rule in Daitōtei on 18 June 1895, and moved to its present location in 1898.

There are 2,400 beds in Department of Internal Medicine, National Taiwan University Hospital.

During the past decade, Department of Internal Medicine, National Taiwan University Hospital conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 6 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Department of Internal Medicine, National Taiwan University Hospital" #1 sponsor was "National Taiwan University Hospital" with 22 trials, followed by "Hoffmann-La Roche" with 6 trials sponsored, "Pfizer" with 4 trials sponsored, "Al-Azhar University" with 1 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Department of Internal Medicine, National Taiwan University Hospital" #1 collaborator was "Department of Health, Executive Yuan, R.O.C. (Taiwan)" with 3 trials as a collaborator, "National Science Council, Taiwan" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Microbio Co Ltd" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Department of Internal Medicine, National Taiwan University Hospital" are "Carcinoma, Non-Small-Cell Lung" (2 trials), "Chronic Hepatitis B" (2 trials), "Duodenal Ulcer" (2 trials), "Non-Small Cell Lung Cancer" (2 trials) and "Non-Squamous Non-Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Department of Internal Medicine, National Taiwan University Hospital" in a lesser frequency.

Most popular intervention types in "Department of Internal Medicine, National Taiwan University Hospital" are "Drug" (21 trials), "Other" (4 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (4 trials), "Placebo" (4 trials), "Carboplatin" (3 trials), "Docetaxel" (3 trials) and "Pemetrexed" (3 trials). Other intervention names were less common.

The vast majority of trials in "Department of Internal Medicine, National Taiwan University Hospital" are 33 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Department of Internal Medicine, National Taiwan University Hospital". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Department of Internal Medicine, National Taiwan University Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Department of Internal Medicine, National Taiwan University Hospital, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 7 trials that are defined as “Not Applicable".